Peptide-based medicines have become one of the fastest-growing areas of modern drug development. From insulin and hormone therapies to GLP-1 medicines and treatments for rare genetic diseases, FDA-approved peptide therapeutics now cover a wide range of medical conditions.
At the same time, the growing popularity of peptides has created significant confusion between FDA-approved medicines, investigational compounds, compounded products, and research-use peptides.
This guide explains the current FDA peptide landscape in 2026, including major approved peptide medicines, recently approved therapies, popular research peptides that are not FDA approved, and promising compounds still in clinical development.
Important: FDA approval applies to a specific drug product and its approved indications. A peptide being chemically similar to an approved medicine—or being sold as a “research peptide”—does not make it FDA approved for human use.
What Is an FDA-Approved Peptide?
There is no single FDA-maintained webpage that serves as a definitive, consolidated “FDA-approved peptide list.” Different peptide databases also use different definitions when determining which medicines qualify as peptides.
For example, FDA's commonly used structural definition distinguishes peptides from proteins based on chain length, while broader pharmaceutical classifications can include peptide-related drugs, peptide analogs, diagnostic agents, and other TIDES compounds.
As a result, published estimates can vary substantially depending on the methodology. One recent 2026 review describes approximately 130 peptide-related therapeutics, while a narrower independent census of Drugs@FDA identifies a much smaller group of peptide active ingredients under a specific ≤40-amino-acid definition.
The most important point is therefore not the headline number—it is whether a specific product has FDA approval for a specific indication.
Major FDA-Approved Peptide Medicines
Some of the most clinically important peptide medicines currently approved in the United States include:
Active Ingredient | Common Brand Names | Major FDA-Approved Uses |
Semaglutide | Ozempic, Rybelsus, Wegovy | Type 2 diabetes; chronic weight management and other approved cardiovascular/metabolic indications |
Tirzepatide | Mounjaro, Zepbound | Type 2 diabetes; chronic weight management and other approved indications |
Liraglutide | Victoza, Saxenda | Type 2 diabetes; weight management |
Dulaglutide | Trulicity | Type 2 diabetes; cardiovascular risk reduction |
Exenatide | Byetta, Bydureon | Type 2 diabetes |
Teriparatide | Forteo, Bonsity | Osteoporosis |
Abaloparatide | Tymlos | Osteoporosis |
Octreotide | Sandostatin, Mycapssa | Acromegaly and certain other approved indications |
Lanreotide | Somatuline Depot | Acromegaly and neuroendocrine tumors |
Pasireotide | Signifor | Cushing's disease and acromegaly |
Leuprolide | Lupron Depot | Prostate cancer, endometriosis, precocious puberty and other hormone-sensitive conditions |
Goserelin | Zoladex | Prostate cancer, breast cancer and endometriosis |
Degarelix | Firmagon | Advanced prostate cancer |
Icatibant | Firazyr | Acute hereditary angioedema attacks |
Ziconotide | Prialt | Severe chronic pain requiring intrathecal administration |
Bremelanotide | Vyleesi | Hypoactive sexual desire disorder in premenopausal women |
Afamelanotide | Scenesse | Erythropoietic protoporphyria |
Setmelanotide | Imcivree | Specific genetic, syndromic and hypothalamic obesity indications |
Vosoritide | Voxzogo | Achondroplasia |
Difelikefalin | Korsuva | Moderate-to-severe pruritus in certain hemodialysis patients |
Trofinetide | Daybue | Rett syndrome |
Palopegteriparatide | Yorvipath | Hypoparathyroidism |
Elamipretide | Forzinity | Barth syndrome |
These examples illustrate how broad the approved peptide-drug category has become, extending well beyond the familiar GLP-1 class.
GLP-1 and Related Peptide Medicines
The most commercially visible peptide medicines today are metabolic therapies.
Semaglutide
Semaglutide is available under several FDA-approved brand names, including Ozempic, Rybelsus, and Wegovy. Depending on the product, formulation, and indication, semaglutide is used for type 2 diabetes, chronic weight management, and other approved cardiovascular or metabolic indications.
Rybelsus is particularly notable because it provides an oral formulation of semaglutide, demonstrating that peptide medicines do not always have to be administered by injection.
Tirzepatide
Tirzepatide is marketed as Mounjaro for type 2 diabetes and Zepbound for chronic weight management and other approved indications.
Tirzepatide is a dual GIP/GLP-1 receptor agonist, distinguishing it from traditional GLP-1-only medicines.
Liraglutide
Liraglutide is another established GLP-1 receptor agonist marketed as Victoza and Saxenda for different approved indications.
Setmelanotide
Setmelanotide, marketed as Imcivree, is an important example of why the phrase “FDA-approved peptides for weight loss” requires qualification.
Imcivree is not a general-purpose weight-loss drug. It is an MC4 receptor agonist approved for specific forms of obesity associated with conditions such as:
POMC deficiency
PCSK1 deficiency
LEPR deficiency
Bardet-Biedl syndrome
Acquired hypothalamic obesity
The FDA-approved indication includes specific age, genetic and clinical criteria. It should therefore not be grouped with medicines approved for general or polygenic obesity.
Newer Peptide-Related Approvals: 2024–2025
The peptide therapeutic landscape has continued to expand beyond metabolic medicine.
Palopegteriparatide — Yorvipath
Palopegteriparatide, marketed as Yorvipath, was approved in 2024 for adults with hypoparathyroidism.
It is a long-acting PTH-related therapy designed to provide sustained parathyroid hormone activity.
Levacetylleucine — Aqneursa
Aqneursa (levacetylleucine) was approved in 2024 for neurological manifestations associated with Niemann-Pick disease type C.
Because classification methodologies differ, products such as this should be evaluated individually rather than automatically included in every “peptide” count.
Pegulicianine — Lumisight
Lumisight (pegulicianine) is a diagnostic imaging agent used as an adjunct during breast cancer surgery to help identify cancerous tissue.
This is another example of why a broad peptide-drug list can include diagnostic as well as therapeutic applications.
Elamipretide — Forzinity
Elamipretide, marketed as Forzinity, received FDA approval in 2025 for Barth syndrome.
It represents an important development in rare-disease medicine and demonstrates the expanding range of peptide-based therapeutic approaches.
Is Tesamorelin an FDA-Approved Peptide?
Tesamorelin, marketed as Egrifta, is FDA approved for reducing excess abdominal fat in adults with HIV-associated lipodystrophy.
However, it is an important classification boundary case.
Under the ≤40-amino-acid definition used in some peptide censuses, tesamorelin falls outside the peptide category because it contains 44 amino acids and is therefore classified as a protein under that particular definition.
This does not mean tesamorelin is unapproved. It means that the answer depends on whether the question is:
“Is tesamorelin FDA approved?”
Yes.
Or:
“Is tesamorelin included in a specific ≤40-amino-acid FDA peptide census?”
Not necessarily.
That distinction is important when comparing peptide lists.
Popular Research Peptides That Are Not FDA Approved
The popularity of research peptides has grown rapidly, but many compounds promoted online do not have FDA approval for human therapeutic use.
Examples include:
Research Peptide | FDA Approval Status |
BPC-157 | Not FDA approved |
TB-500 | Not FDA approved |
CJC-1295 | Not FDA approved |
Ipamorelin | Not FDA approved |
MOTS-c | Not FDA approved |
KPV | Not FDA approved |
Epitalon | Not FDA approved |
Selank | Not FDA approved |
Semax | Not FDA approved |
GHK-Cu injectable | Not FDA approved |
GHRP-2 | Not FDA approved |
GHRP-6 | Not FDA approved |
AOD-9604 | Not FDA approved |
DSIP | Not FDA approved |
LL-37 | Not FDA approved |
PEG-MGF | Not FDA approved |
These compounds should not be described as FDA-approved treatments simply because they are widely discussed online, have published laboratory research, or are sold by peptide vendors.
FDA approval requires regulatory authorization for a specific drug product and indication.
BPC-157: Is It FDA Approved?
No.
BPC-157 is not FDA approved for human therapeutic use.
The same distinction applies to many other popular research peptides. A compound can be the subject of scientific research without having FDA approval.
Consumers should therefore be cautious when websites use phrases such as:
“FDA peptide”
“FDA-approved peptide”
“pharmaceutical-grade peptide”
“clinical-grade peptide”
“doctor-formulated peptide”
Such marketing language does not necessarily mean the product itself has received FDA approval.
TB-500 vs. Bremelanotide: An Important Distinction
Another common source of confusion involves TB-500 and PT-141/bremelanotide.
TB-500 is not FDA approved.
Bremelanotide, however, is FDA approved under the brand name Vyleesi for a specific indication: hypoactive sexual desire disorder in premenopausal women.
Therefore, the fact that two compounds may be discussed in similar research or peptide communities does not mean they share the same regulatory status.
2026 Peptide Pipeline: What Is Still Investigational?
Several high-profile peptide and peptide-combination therapies remain in development.
Retatrutide
Retatrutide is an investigational triple agonist targeting:
GIP
GLP-1
Glucagon
It is being developed primarily for obesity and metabolic disease.
Retatrutide is not FDA approved as of 2026.
CagriSema
CagriSema combines cagrilintide and semaglutide.
It remains an investigational therapy rather than an FDA-approved drug.
Survodutide
Survodutide is an investigational dual GLP-1/glucagon receptor agonist being studied for obesity and metabolic liver disease, including MASH.
It is not FDA approved.
Cagrilintide
Cagrilintide is another investigational metabolic peptide being studied independently and in combination with semaglutide.
It should not be represented as an FDA-approved weight-loss medication.
Other Investigational Programs
The broader development pipeline also includes compounds such as:
Mazdutide
Eneboparatide
Other next-generation metabolic receptor agonists
Long-acting hormone analogs
Novel peptide delivery technologies
Clinical development status can change quickly, so investigational compounds should always be checked against current FDA and clinical-trial information.
FDA Approval vs. Compounding vs. Research Use
One of the most important distinctions in the peptide industry is that these are three different regulatory concepts:
1. FDA-approved medicine
A specific drug has been reviewed and approved by FDA for specified uses.
2. Compounded medication
A pharmacy or outsourcing facility may prepare a compounded product under applicable federal and state requirements. Compounding does not automatically mean the resulting product has FDA approval.
3. Research-use peptide
A compound may be sold for laboratory or research purposes without FDA approval for human therapeutic use.
These categories should never be treated as interchangeable.
GLP-1 Compounding Changes
FDA's resolution of shortages involving semaglutide and tirzepatide resulted in significant changes to the compounding landscape.
According to the 2026 source material, tirzepatide was removed from the FDA shortage list in October 2024, followed by deadlines affecting 503A and 503B compounders in 2025. Semaglutide's shortage was resolved in February 2025, with subsequent enforcement changes affecting compounded versions.
The key takeaway for 2026 is that the existence of an FDA-approved active ingredient does not automatically mean that any compounded version of that ingredient is FDA approved or legally interchangeable with the approved product.
2026 Regulatory Watch
The regulatory environment surrounding peptides continues to evolve.
In addition to FDA-approved products and clinical trials, regulators are examining questions surrounding the compounding of certain peptide substances.
This is particularly important for compounds such as:
CJC-1295
Ipamorelin
AOD-9604
Thymosin Alpha-1
Their regulatory status should be monitored separately from the status of FDA-approved medicines.
A potential compounding policy or regulatory review would not automatically convert an investigational peptide into an FDA-approved drug.
FDA-Approved Peptides vs. Research Peptides
The simplest way to understand the market is to separate products into two groups:
Category | Examples | FDA Approved? |
Approved metabolic medicines | Semaglutide, tirzepatide, liraglutide | Yes |
Approved hormone/peptide therapies | Teriparatide, abaloparatide, leuprolide | Yes |
Approved rare-disease therapies | Setmelanotide, trofinetide, palopegteriparatide, elamipretide | Yes |
Investigational metabolic peptides | Retatrutide, survodutide, cagrilintide | No |
Research peptides | BPC-157, TB-500, CJC-1295, ipamorelin | No |
Injectable GHK-Cu | Research use | No |
What Does “FDA Approved” Actually Mean?
This is perhaps the most important question for consumers and researchers.
FDA approval is associated with a specific drug product, manufacturer/application, formulation, dosage, and approved indication.
Therefore:
An FDA-approved peptide does not mean every vial containing that peptide is FDA approved.
For example, the fact that semaglutide is an FDA-approved active ingredient does not mean that every semaglutide product sold online is an FDA-approved drug.
Likewise, an investigational compound such as retatrutide does not become FDA approved simply because it has entered Phase 3 clinical trials.
Frequently Asked Questions About FDA-Approved Peptides in 2026
1. What peptides are FDA approved?
The FDA does not publish a single, consolidated list of approved peptide drugs. Under a commonly used definition that classifies peptides as chains of 40 amino acids or fewer, an independent census identifies approximately 43 FDA-approved peptide active ingredients, with 37 still having a marketed product. Examples include semaglutide, tirzepatide, liraglutide, teriparatide, octreotide, leuprolide, setmelanotide, trofinetide, and elamipretide. The total depends on the definition used and which drug products are included.
2. Is semaglutide FDA approved?
Yes. Semaglutide is FDA approved under several brand names, including Ozempic, Rybelsus, and Wegovy. Each product has its own approved indications and formulation. FDA approval of these products does not automatically extend to compounded or research-labeled semaglutide.
3. Is tirzepatide FDA approved?
Yes. Tirzepatide is FDA approved as Mounjaro for type 2 diabetes and as Zepbound for chronic weight management and certain other approved indications, including obstructive sleep apnea in eligible adults with obesity.
The approval applies to the specific authorized products and indications, not every product marketed as tirzepatide.
4. Is retatrutide FDA approved in 2026?
No. Retatrutide remains an investigational medication being studied for obesity and metabolic conditions. It activates GIP, GLP-1, and glucagon receptors, but it has not received FDA approval as a finished drug product.
Clinical-trial participation or promising research findings do not mean a medicine is approved for general use.
5. Is BPC-157 FDA approved?
No. BPC-157 is not FDA approved for treating any medical condition.
The FDA has identified potential safety concerns involving compounded BPC-157, including immunogenicity, peptide-related impurities, difficulties characterizing the active ingredient, and limited human safety information.
A favorable advisory committee recommendation concerning compounding would not, by itself, change BPC-157's FDA drug-approval status.
6. Is TB-500 FDA approved?
No. TB-500 is not an FDA-approved drug for human therapeutic use. Research involving thymosin-related compounds should not be confused with approval of TB-500 itself.
Its availability or discussion in research settings does not establish safety or effectiveness in humans.
7. Is CJC-1295 FDA approved?
No. CJC-1295 is not FDA approved for human therapeutic use. It is discussed in research related to growth hormone pathways, but research interest does not establish an approved indication or a reliable human safety profile.
8. Is ipamorelin FDA approved?
No. Ipamorelin is not an FDA-approved treatment for any medical condition. It is an investigational compound, and claims about its benefits should be distinguished from evidence obtained through adequate human clinical trials.
9. What new peptide-related medicines were approved in 2024 and 2025?
Recent peptide-related or peptide-associated approvals include:
Palopegteriparatide (Yorvipath): Approved in 2024 for adults with hypoparathyroidism.
Elamipretide (Forzinity): Approved in 2025 for eligible patients with Barth syndrome.
Other notable drug approvals during this period include levacetylleucine (Aqneursa) for Niemann-Pick disease type C and pegulicianine (Lumisight), a diagnostic imaging agent used during breast cancer surgery. Their inclusion in a peptide list depends on the classification criteria being used.
10. Are compounded peptides FDA approved?
No. Compounded medications are not FDA-approved drug products, even when they contain an ingredient also found in an FDA-approved medicine.
Whether a particular substance may be compounded depends on applicable federal and state requirements, the type of pharmacy, and the substance's regulatory status. FDA approval of a branded medicine does not automatically authorize copies or compounded versions.
For peptides under review, such as BPC-157, a committee recommendation does not independently establish compounding eligibility.
11. Are research peptides FDA approved?
Generally, no. Many peptides marketed for research purposes do not have FDA-approved drug applications for human therapeutic use.
Examples include BPC-157, TB-500, CJC-1295, ipamorelin, MOTS-c, KPV, epitalon, selank, semax, injectable GHK-Cu, GHRP-2, GHRP-6, and AOD-9604.
A “research use only” label does not mean a product has been approved, demonstrated safe for human administration, or authorized as a treatment.
12. How can I check whether a peptide is FDA approved?
Use the FDA's official Drugs@FDA database.
Search for the active ingredient and brand name, then review the approved product, application information, prescribing information, and approved indications.
Be cautious when relying on third-party peptide lists because definitions vary. Some include larger proteins, insulin, diagnostic agents, or other peptide-related compounds, while narrower lists apply a specific amino-acid cutoff.
13. Does FDA approval mean a peptide is safe for everyone?
No. FDA approval means that the agency has determined that a particular drug's benefits outweigh its risks for its approved uses, based on the available evidence.
An approved medicine can still cause adverse effects and may not be suitable for every person. Safety depends on the specific product, indication, dose, patient characteristics, and other medications or medical conditions.
Approval also does not establish that a product is appropriate for unsupervised use or for indications outside its approved labeling.
14. What is the difference between FDA-approved, compounded, and research-use peptides?
These terms describe different regulatory categories.
Category | FDA-approved drug? | What it means |
FDA-approved medicine | Yes | A specific product has been approved for specified indications. |
Compounded medication | No | Prepared under applicable compounding requirements; not FDA approved as a finished drug. |
Research-use compound | No, unless separately approved | Intended for legitimate research purposes, not established as a human treatment. |
A compound may have promising laboratory findings or be under clinical investigation without being approved for medical use.
15. Which investigational peptides should readers watch in 2026?
Several investigational programs are attracting attention in metabolic medicine:
Retatrutide: A triple GIP/GLP-1/glucagon receptor agonist being studied for obesity and metabolic conditions.
Survodutide: A dual GLP-1/glucagon receptor agonist being investigated for obesity and metabolic liver disease.
Cagrilintide: An amylin-based investigational therapy being studied for metabolic conditions and weight management.
CagriSema: A combination of cagrilintide and semaglutide being investigated for obesity and related metabolic conditions.
These candidates should not be described as FDA-approved medicines unless their approval is confirmed in current FDA records.
16. Is tesamorelin FDA approved?
Yes. Tesamorelin, marketed as Egrifta, is FDA approved for a specific indication involving excess abdominal fat in adults with HIV-associated lipodystrophy.
However, tesamorelin contains 44 amino acids, so it falls outside the strict definition used by peptide censuses that include only chains of 40 amino acids or fewer. This is a classification distinction, not a statement that the medicine is unapproved.
17. How many FDA-approved peptide drugs are there?
There is no single official FDA-published total for peptide drugs. One independent census using a definition of 40 amino acids or fewer identifies 43 approved peptide active ingredients, of which 37 still have a marketed product.
Other sources may report different totals because they include different categories of medicines, proteins, diagnostic products, or peptide-related compounds.
18. What is the most important thing to know about FDA-approved peptides?
FDA approval applies to a specific drug product and its approved indications—not simply to an ingredient name or the fact that a compound has been researched.
Before relying on a peptide-related health claim, verify its regulatory status using official FDA records and distinguish approved medicines from compounded products and investigational compounds.
Disclaimer: This FAQ is for educational purposes only and is not medical advice. Regulatory status can change; consult current FDA records for the latest information.
Final Takeaway
The peptide landscape in 2026 is expanding rapidly, but the market contains several very different categories of products.
FDA-approved peptide medicines include established therapies such as semaglutide, tirzepatide, liraglutide, teriparatide, setmelanotide and many others.
Meanwhile, compounds such as BPC-157, TB-500, CJC-1295, ipamorelin, MOTS-c, AOD-9604, cagrilintide, survodutide and retatrutide remain outside FDA-approved drug status.
The distinction matters.
A peptide being popular, commercially available, studied in clinical trials, sold by a research supplier, or discussed by healthcare professionals does not by itself establish FDA approval.
For the most accurate regulatory assessment, always verify the specific product, FDA application, formulation and approved indication rather than relying solely on a general “FDA-approved peptide” label.
Research and regulatory information changes frequently. This article is intended for educational purposes and should not be used as a substitute for current FDA labeling, regulatory guidance, or professional medical advice.
Reference:
FDA-approved peptides full list: https://peptifact.com/fda-approved-peptides
Peptide FDA status hub: https://www.peptidestack.io/peptide-fda-status-hub
Tirzepatide unit converter: https://peptidestack.io/tools/tirzepatide-dosage-calculator
Retatrutide approval status: https://peptidestack.io/peptide-fda-status-hub
BPC-157 FDA approval status: https://peptidestack.io/blog/bpc-157-fda-approval-status
New FDA-approved peptides (2026): https://www.livenowlongevity.com/new-fda-approved-peptides
FDA-approved peptide tracker for providers: https://iapam.com/peptide-therapy-for-providers/fda-approved-peptides-2026
Therapeutic peptides list: https://peptidestack.io/blog/therapeutic-peptides-list
Peptide approval guide: https://www.peptideschool.org/blog/peptide-approval-guide
FDA peptide approval tracker: https://highpeptides.com/research/fda-approval-tracker/
